Ardelyx Q1 product revenue rises 38% on IBSRELA growth

Ardelyx

30/04/2026 21:34

Overview

U.S. biopharma firm's Q1 product revenue rose 38% yr/yr, driven by IBSRELA growth

Company's net loss narrowed to $37.6 mln from $41.1 mln a year earlier

Company reiterated 2026 revenue guidance for IBSRELA and XPHOZAH

Outlook

Ardelyx reiterates 2026 IBSRELA revenue guidance of $410-$430 mln

Company maintains 2026 XPHOZAH revenue guidance of $110-$120 mln

Company expects ACCEL Phase 3 trial enrollment to complete by end-2026, topline data in H2 2027

Result Drivers

IBSRELA DEMAND - Growth in IBSRELA revenue was driven by increases in total writers, new and refill prescriptions, and improved prescription pull-through

XPHOZAH PAID PRESCRIPTIONS - XPHOZAH revenue was driven by a strong increase in paid prescriptions

Company press release: ID:nGNX6js6Jm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Sales
$93.37 mln
Q1 Net Income
-$37.61 mln
Q1 Operating Income
-$32.79 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ardelyx Inc is $16.50, about 174.5% above its April 29 closing price of $6.01

The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 37 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)